Dual targeting of FGFR3 and ERBB3 enhances the efficacy of FGFR inhibitors in FGFR3 fusion-driven bladder cancer by Andrew J. Weickhardt, David K. Lau, Margeaux Hodgson-Garms, Austen Lavis, Laura J. Jenkins, Natalia Vukelic, Paul Ioannidis, Ian Y. Luk, John M. Mariadason

Get full text